Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Waldenström’s Macroglobulinemia venetoclax therapy

Jorge Castillo • 13 Sep 2019
IMW 2019
Multiple Myeloma Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib Venetoclax

Jorge Castillo, MD Dana-Farber Cancer Institute, Boston, MA, provides an update on phase II trials of venetoclax therapy as a treatment for Waldenström’s Macroglobulinemia patients, alongside an overview of the disease biology. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Jorge Castillo

Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Two-year follow-up after ibrutinib plus venetoclax in symptomatic treatment-naive WM 3:13
Two-year follow-up after ibrutinib plus venetoclax in symptomatic treatment-naive WM
Jorge Castillo • 7 Dec 2024
Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM 2:25
Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM
Jorge Castillo • 7 Dec 2024

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals